BUSINESS WIRE--Banner Pharmacaps Inc., a leader in the pharmaceutical industry for the development of soft gelatin dosage form technology, announces that the US Food & Drug Administration granted approval for the Company’s Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride USP 100 mg soft gelatin capsules on May 29, 2008.
Amantadine is indicated for the prophylaxis and treatment of signs and symptoms of infection in the respiratory tract caused by various strains of influenza A virus. Amantadine is also utilized in the treatment of Parkinson’s Disease and drug-induced extrapyramidal reactions.
No comments:
Post a Comment